🇺🇸 Flavopiridol in United States
47 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 47
Most-reported reactions
- Lymphopenia — 7 reports (14.89%)
- Diarrhoea — 5 reports (10.64%)
- Febrile Neutropenia — 5 reports (10.64%)
- Nausea — 5 reports (10.64%)
- Neutropenia — 5 reports (10.64%)
- Off Label Use — 5 reports (10.64%)
- Hypophosphataemia — 4 reports (8.51%)
- Malignant Neoplasm Progression — 4 reports (8.51%)
- Tumour Lysis Syndrome — 4 reports (8.51%)
- Anaemia — 3 reports (6.38%)
Other Other approved in United States
Frequently asked questions
Is Flavopiridol approved in United States?
Flavopiridol does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Flavopiridol in United States?
National Cancer Institute (NCI) is the originator. The local marketing authorisation holder may differ — check the official source linked above.